Browse > Article
http://dx.doi.org/10.4333/KPS.2007.37.2.107

The Effect of Long-term Administration of Epigallocatechin on the Pharmacokinetics of Verapamil in Rats  

Yun, Jae-Kyung (College of Pharmacy, Chosun University)
Choi, Jun-Shik (College of Pharmacy, Chosun University)
Publication Information
Journal of Pharmaceutical Investigation / v.37, no.2, 2007 , pp. 107-111 More about this Journal
Abstract
Epigallocatechin gallate (EGCC), a flavonoid, is the main component of green tea extracts. EGCG has been reported to be an inhibitor of P-glycoprotein (P-gp) and cytochrom P450 3A(CYP3A4). This study investigated the effect of long-term administration of EGCG on the pharmacokinetics of verapamil in rats. Pharmacokinetic parameters of verapamil were determined after oral administration of verapamil (9 mg/kg) in rats pretreated with EGCG (7.5 mg/hg) for 3 and 9 days. Compared to oral control group, the presence of EGCG significantly (p<0.01) increased the area under the plasma concentration-time curve (AUC) of verapamil by 102% (coad), 83.2% (3 days) and 52.3% (9 days), and the peak concentration $(C_{max})$ by 134% (coad), 120% (3 days) and 66.1% (9 days). The absolute bioavailability (A.B.%) of verapamil was significantly (p<0.01) higher by 8.4% (coad), 7.7% (3 days), 6.4% (9 days) compared to control (4.2%), and presence of EGCG was no significant change in the terminal half-life $(t_{1/2})$ and the time to reach the peak concentration $(T_{max})$ of verapamil. Our results indicate that EGCG significantly enhanced oral bioavailability of verapamil in rats, implying that presence of EGCG could be effective to inhibit the CYP3A4-mediated metabolism and P-gp efflux of verapamil in the intestine. Drug interactions should be considered in the clinical setting when verapamil is coadministrated with EGCG or EGCG-containing dietary.
Keywords
Verapamil; (-)Epigallocatechin gallate (EGCG); Pharmacokinetics; P-gp; CYP3A; Rats;
Citations & Related Records
연도 인용수 순위
  • Reference
1 A. Fleckenstein, Specific pharmacology of calcium in myocardium. cardiac pacemakers, and vascular smooth muscle, Annual Review of Pharmacology and Toxicology, 17, 149-166 (1977)   DOI   ScienceOn
2 D. M. Krikler and R. A. J. Spurrel, verapamil in the treatment of paroxysmal supraventricular tachycardias, Postgraduate Medicine, 50, 447-453 (1974)   DOI   ScienceOn
3 B. A. Gould, S. Mann, H. Kieso, V. Bala Subramanian and E. B. Raftery, The 24-hour ambulatory blood pressure profile with verapamil, Circulation, 65, 22-27 (1982)   DOI   ScienceOn
4 G. R. J. Lewis, K. D. Morley, B. M. Lewis and P. J. Bones, The treatment of hypertension with verapamil, N.Z. Medical Journal, 87, 351-354 (1978)
5 M. Eichelbaum. E. G. Remberg, M. Schomerus and H. J. Dengler, The metabolism of D,L$(^{14}C)$ verapamil in man, Drug Metabolism and Disposition, 7, 145-148 (1979)
6 M. Eichelbaum, G. Mikus and B. Vogelgesang, Pharmacokinetics of (+)-,(-)- and $({\pm})$-verapamil after intravenous administration, British Journal of Clinical Pharmacology, 17, 453-458 (1984)   DOI   ScienceOn
7 B. G. Woodcock, I. Rietbrock, H. Voehringer and N. Rietbrock, Verapamil disposition in liver disease and intensive-case patients: kinetics, clearance, and apparent blood flow relationships, Clinical Pharmacology and Therapeutics, 29, 27-34 (1981)   DOI   ScienceOn
8 M. Eichelbaum, M. Albrecht, K. Kliems, K. Schafe and A. Somogyi, Influence of mesocaval shunt surgery on verapamil kinetics, bioavailability and response, British Journal of Clinical Pharmacology, 10, 527-529 (1980)   DOI   ScienceOn
9 J. B. Schwartz, D. R. Abernethy, A. A. Taylor and J. R. Mitchel, An investigation of the cause of accumulation of verapamil during regular dosing in patients, British J Clinical Pharmacology, 19, 512-516 (1985)   DOI   ScienceOn
10 M. Eichelbaum, P. Birkel, E. Grube, U. Gutgemann and A. Somogyi, Effects of verapamil on PR intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment, Klinische Wochenschrift, 58, 919-925 (1980)   DOI
11 U. Fuhr, H. Muller-Peltzer, R. Kern and S. Harder, Effect of grapefruit juice and smoking on verapamil concentration steady state, Eur. J. Clin. Pharmacol., 58, 45-53 (2002)   DOI   ScienceOn
12 G. Mikus, Die Anwendung eines mit stabilen isotopen markierten Arzneimittels zur simultanen Bestimmung der relativen biologischem Verfugbarkeit einer verapamil retard, Thesis, University of Bonn., (1985)
13 J. A. Dominic, D. W. A. Bourne, T. G Tan, E. B. Kirsten and R. G. McAllister, The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration, J. Cardiovascular Pharmacology, 3, 25-38 (1981)   DOI   ScienceOn
14 P. C. Ho, K. Ghose, D. Saville and S. Wanwimolruk, Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers, Eur. J Clin. Pharmacol., 56, 693-698 (2000)   DOI   ScienceOn
15 R. Sandstrom, A. Karlsson, L. Knutson and H. Lennemas, Jejunal absorption and metabolism of R/S-verapamil in humans, Pharm. Res., 15, 856-862 (1998)   DOI   ScienceOn
16 V. J. Wacher, C. Y. Wu and L. Z. Benet, Overlapping substrate specificities and tissue distribution of cytochrome p450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinog., 13, 129-134 (1995)   DOI   ScienceOn
17 D. C. Chu and L. R. Juneja, Chemistry and Applications of Green Tea, in: T. Yamamoto, L.R. Juneja, D.C. Chu and M. Kim, (Eds.), CRC Press, New York, pp. 1322 (1997)
18 C. M. Loi, D. E. Rollins, G. E. Dukes and M. A. Peat, Effect of cimetidine on verapamil disposition, Clin. Pharm. and Therapeutics, 37, 654-657 (1985)   DOI   ScienceOn
19 M. Schomerus, B. Spiegelhaider, B. Stieren and M. Eichelbaum, Physiologic disposition of verapamil in man, Cardiovascular Research, 10, 605-612 (1976)   DOI   ScienceOn
20 G. Neugebauer, Comparative cardiovascular actions of verapamil and its major metabolites in the anesthetized dog, Cardiovascular Research, 12, 247-254 (1978)   DOI   ScienceOn
21 L. M. Johnson, S. M. Lankford and S. A. Bai, The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing, J. Vet. Pharmacal. Ther., 18, 117-123 (1995)   DOI   ScienceOn
22 J. Hong, J. D. Lambert, S. H. Lee, P. J. Sinko and C. S. Yang, Involvement of multidrug resistance-associated proteins in regulating cellular levels of (- )-epigallocatechin-3-gallate and its methyl metabolites, Biochem. Biophys. Res. Commun., 310, 222-227 (2003)   DOI   ScienceOn
23 S. Kitagawa, T. Nabekura and S. Kamiyama, Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells, J. Pharm. Pharmacol., 56, 1001-1005 (2004)   DOI   ScienceOn
24 식품의약품안전청, 국립독성연구소, 생물학적동등성시험 표준지침. 식품의약품안전청, pp. 142-146 (2003)
25 M. L. Rocci and W. J. Jusko, LAGRAN program for area and moments in pharmacokinetic analysis, Computer Programs in Biomedicine, 16, 203-209 (1983)   DOI   ScienceOn
26 H. J. Kim and J. S. Choi, Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits, Biopharm. Drug Dispos., 26, 295-300 (2005)   DOI   ScienceOn
27 F. X. McGowan, M. J. Reiter, E. L. C. Pritchett and D. G. Shand, Verapamil plasma binding: Relationship to $alpha_1$ acid glycoprotein and drug efficacy, Clinical Pharmacology and Therapeutics, 33, 485-490 (1983)   DOI   ScienceOn
28 J. S. Choi and H. K. Han, The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. J. Pharm. Pharmacol., 56, 1537-1542 (2004)   DOI   ScienceOn
29 S. B. Freedman, D. R. Richmond, J. J. Ashley and D. T. Kelly, Verapamil kinetics in normal subjects and patients with coronary artery spasm., Clinical Pharmacology and Therapeutics, 30, 644-652 (1981)   DOI   ScienceOn
30 R. G. McAllister, Clinical pharmacology of slow channel blocking agents, Progress in Cardiovascular Diseases, 25, 83-102 (1982)   DOI   ScienceOn
31 D. L. Keefe, Y. G. Yee and R. E. Kates, Verapamil protein binding in patients and in normal subjects, Clin. Pharm. and Therapeutics, 29, 21-26 (1981)   DOI   ScienceOn
32 J. Jodoin, M. Demeule and R. Beliveau, Inhibition of the mutldrug resistance P-glycoprotein activity by green tea polyphenols, Biochim. Biophys. Acta, 1542, 149-159 (2002)   DOI   ScienceOn
33 J. V. Higdon and B. Frei, Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions, Crit. Rev. Food Sci. Nutr., 43, 89-143 (2003)   DOI   ScienceOn
34 Y. Kuroda and Y. Hara, Antimutagenic and anticarcinogenic activity of tea polyphenols, Mutat. Res., 436, 69-97 (1999)   DOI   ScienceOn
35 S. Muto, K. Fujita, Y. Yamazaki and T. Kamataki, Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450, Mutat. Res., 479, 197-206 (2001)   DOI